header logo image


Page 6«..5678..2030..»

Archive for April, 2020

Lysogene S.A. (EPA:LYS): When Will It Breakeven? – Simply Wall St

Tuesday, April 28th, 2020

Lysogene S.A.s (EPA:LYS): Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. The 64m market-cap company announced a latest loss of -4.3m on 31 December 2019 for its most recent financial year result. Many investors are wondering the rate at which LYS will turn a profit, with the big question being when will the company breakeven? Below I will provide a high-level summary of the industry analysts expectations for LYS.

Check out our latest analysis for Lysogene

According to the industry analysts covering LYS, breakeven is near. They expect the company to post a final loss in 2021, before turning a profit of 69m in 2022. LYS is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, I calculated the rate at which LYS must grow year-on-year. It turns out an average annual growth rate of 50% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, LYS may become profitable much later than analysts predict.

Im not going to go through company-specific developments for LYS given that this is a high-level summary, however, keep in mind that by and large a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

One thing Id like to point out is that LYS has managed its capital judiciously, with debt making up 13% of equity. This means that LYS has predominantly funded its operations from equity capital,and its low debt obligation reduces the risk around investing in the loss-making company.

There are too many aspects of LYS to cover in one brief article, but the key fundamentals for the company can all be found in one place LYSs company page on Simply Wall St. Ive also put together a list of relevant aspects you should further research:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more:
Lysogene S.A. (EPA:LYS): When Will It Breakeven? - Simply Wall St

Read More...

BRIEF-Novartis CEO Says Still Need Proper Blinded Studies To Determine Which Drugs Have Benefit for COVID-19 – Reuters UK

Tuesday, April 28th, 2020

April 28 (Reuters) - Novartis AG:

* NOVARTIS CEO SAYS CORONAVIRUS IMPACTS ARE GREATEST ON NEW CLINICAL STUDY STARTS, SAYS MANAGING SITUATION VIA DIGITAL TECHNOLOGY

* NOVARTIS CEO SAYS INCREASING REMOTE MONITORING OF PATIENTS IN CLINICAL STUDIES

* NOVARTIS CEO SAYS REGULATORS HAVE COMMITTED TO MAINTAINING TIMELINES FOR NEW MEDICINES

* NOVARTIS CEO SAYS BEOVU WAS OFF TO OUTSTANDING LAUNCH, HAS IDENTIFIED RARE SAFETY SIGNAL FOR RETINAL VASCULITIS, STUDYING THE REASON FOR SAFETY SIGNAL, CONTINUES TO BELIEVE MEDICINE WILL EVENTUALLY EXCEED $1 BILLION IN SALES

* NOVARTIS CEO SAYS GUIDANCE ASSUMES HEALTH CARE SYSTEMS WILL RESUME NORMAL OPERATIONS IN Q2

* NOVARTIS CEO SAYS HAS PAUSED ENROLLMENT IN UK INCLISIRAN TRIAL DUE TO CORONAVIRUS PANDEMIC, HOPEFUL TO RESTART IN COMING QUARTERS

* NOVARTIS CEO SAYS SEES SOME SLOWDOWN IN HOSPITAL VISITS IMPACTING LUTATHERA, KYMRIAH, ZOLGENSMA, SAYS DOING BEST TO REACH OUT TO PATIENTS WHO NEED GENE THERAPY

* NOVARTIS CEO SAYS DIFFICULT TO PREDICT HOW PANDEMIC WILL UNFOLD IN COMING YEAR, AS THINGS EVOLVE WILL UPDATE GUIDANCE AS NEEDED

* NOVARTIS CEO SAYS FEW OF STUDIES SO FAR ON THERAPIES FOR CORONAVIRUS HAVE MET GOLD STANDARD OF RANDOMIZED, BLINDED CLINICAL STUDIES, STILL NEED PROPERLY POWERED BLINDED STUDIES TO REALLY DETERMINE MEDICINES HAVE BENEFIT Further company coverage: (Reporting by John Miller)

Go here to see the original:
BRIEF-Novartis CEO Says Still Need Proper Blinded Studies To Determine Which Drugs Have Benefit for COVID-19 - Reuters UK

Read More...

Personalized Gene Therapy Treatment Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2029 – Germany English…

Tuesday, April 28th, 2020

The research study on Global Personalized Gene Therapy Treatment market 2019 presents an extensive analysis of current Personalized Gene Therapy Treatment market size, drivers, trends, opportunities, challenges, as well as key Personalized Gene Therapy Treatment market segments. Further, it explains various definitions and classification of the Personalized Gene Therapy Treatment industry, applications, and chain structure.In continuation of this data, the Personalized Gene Therapy Treatment report covers various marketing strategies followed by key players and distributors. Also explains Personalized Gene Therapy Treatment marketing channels, potential buyers and development history. The intent of global Personalized Gene Therapy Treatment research report is to depict the information to the user regarding Personalized Gene Therapy Treatment market forecast and dynamics for the upcoming years. The Personalized Gene Therapy Treatment study lists the essential elements which influence the growth of Personalized Gene Therapy Treatment industry. Long-term evaluation of the worldwide Personalized Gene Therapy Treatment market share from diverse countries and regions is roofed within the Personalized Gene Therapy Treatment report. Additionally, includes Personalized Gene Therapy Treatment type wise and application wise consumption figures.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

After the basic information, the global Personalized Gene Therapy Treatment Market study sheds light on the Personalized Gene Therapy Treatment technological evolution, tie-ups, acquisition, innovative Personalized Gene Therapy Treatment business approach, new launches and Personalized Gene Therapy Treatment revenue. In addition, the Personalized Gene Therapy Treatment industry growth in distinct regions and Personalized Gene Therapy Treatment R;D status are enclosed within the report.The Personalized Gene Therapy Treatment study also incorporates new investment feasibility analysis of Personalized Gene Therapy Treatment. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Personalized Gene Therapy Treatment market.

Global Personalized Gene Therapy Treatment Market Segmentation 2019: Personalized Gene Therapy TreatmentThe study also classifies the entire Personalized Gene Therapy Treatment market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Personalized Gene Therapy Treatment market is characterized by the existence of well-known global and regional Personalized Gene Therapy Treatment vendors. These established Personalized Gene Therapy Treatment players have huge essential resources and funds for Personalized Gene Therapy Treatment research as well as developmental activities. Also, the Personalized Gene Therapy Treatment manufacturers focusing on the development of new Personalized Gene Therapy Treatment technologies and feedstock. In fact, this will enhance the competitive scenario of the Personalized Gene Therapy Treatment industry.

The Leading Players involved in global Personalized Gene Therapy Treatment market are:

By Therapy (Targeted Treatments and Pharmacogenomics),By Application (Breast Cancer, Brain Cancer, Colorectal Cancer, Certain Childhood Cancers, Gastrointestinal Stromal Tumor, Kidney Cancer, Leukemia, Lymphoma, Melanoma, Lung Cancer, and Multiple Myeloma)By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

Worldwide Personalized Gene Therapy Treatment Market Different Analysis:Competitors Review of Personalized Gene Therapy Treatment Market: Report presents the competitive landscape scenario seen among top Personalized Gene Therapy Treatment players, their company profile, revenue, sales, business tactics and forecast Personalized Gene Therapy Treatment industry situations. Production Review of Personalized Gene Therapy Treatment Market: It illustrates the production volume, capacity with respect to major Personalized Gene Therapy Treatment regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Personalized Gene Therapy Treatment Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Personalized Gene Therapy Treatment target consumer. Supply and Demand Review of Personalized Gene Therapy Treatment Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Personalized Gene Therapy Treatment product type. Also interprets the Personalized Gene Therapy Treatment import/export scenario. Other key reviews of Personalized Gene Therapy Treatment Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Personalized Gene Therapy Treatment players, potential consumers and suppliers. Also, the strengths, opportunities, Personalized Gene Therapy Treatment market driving forces and market restraints are studied in this report.

Highlights of Global Personalized Gene Therapy Treatment Market Report:* This report provides in detail analysis of the Personalized Gene Therapy Treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Personalized Gene Therapy Treatment market. * This study also provides key insights about Personalized Gene Therapy Treatment market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Personalized Gene Therapy Treatment players. * It profiles leading players in the worldwide Personalized Gene Therapy Treatment market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Personalized Gene Therapy Treatment report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Personalized Gene Therapy Treatment marketing tactics. * The world Personalized Gene Therapy Treatment industry report caters to various stakeholders in Personalized Gene Therapy Treatment market. That includes investors, device manufacturers, distributors and suppliers for Personalized Gene Therapy Treatment equipment. Especially incorporates government organizations, Personalized Gene Therapy Treatment research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Personalized Gene Therapy Treatment market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Personalized Gene Therapy Treatment Market Report Provides Comprehensive Analysis of Following: ; Personalized Gene Therapy Treatment Market segments and sub-segments ; Industry size ; Personalized Gene Therapy Treatment shares ; Personalized Gene Therapy Treatment Market trends and dynamics ; Market Drivers and Personalized Gene Therapy Treatment Opportunities ; Supply and demand of world Personalized Gene Therapy Treatment industry ; Technological inventions in Personalized Gene Therapy Treatment trade ; Personalized Gene Therapy Treatment Marketing Channel Development Trend ; Global Personalized Gene Therapy Treatment Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Personalized Gene Therapy Treatment Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225585

Moreover, the report organizes to provide essential information on current and future Personalized Gene Therapy Treatment market movements, organizational needs and Personalized Gene Therapy Treatment industrial innovations. Additionally, the complete Personalized Gene Therapy Treatment report helps the new aspirants to inspect the forthcoming opportunities in the Personalized Gene Therapy Treatment industry. Investors will get a clear idea of the dominant Personalized Gene Therapy Treatment players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

More:
Personalized Gene Therapy Treatment Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2029 - Germany English...

Read More...

Gene Therapy For CNS Disorders Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

Tuesday, April 28th, 2020

Bluebird Bio

Global Gene Therapy For CNS Disorders Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=175792&utm_source=LHN&utm_medium=888

Gene Therapy For CNS Disorders Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Gene Therapy For CNS Disorders industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Gene Therapy For CNS Disorders industry.

-> Furthermore, we will help you to identify any crucial trends to predict Gene Therapy For CNS Disorders market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Gene Therapy For CNS Disorders market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=175792&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Gene Therapy For CNS Disorders market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Gene Therapy For CNS Disorders market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Gene Therapy For CNS Disorders Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Gene Therapy For CNS Disorders Market Size, Gene Therapy For CNS Disorders Market Growth, Gene Therapy For CNS Disorders Market Forecast, Gene Therapy For CNS Disorders Market Analysis

Our Trending Reports

U.S. Pest Control Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Battery Monitoring System Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

The rest is here:
Gene Therapy For CNS Disorders Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Read More...

COVID-19 impact: Gene Therapy Market 2019 Business Insights,Top Companies,Growth, Market Size Global Market Share, Trends, Outlook, Opportunity and…

Tuesday, April 28th, 2020

Analysis Report on Gene Therapy Market

A report on global Gene Therapy market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Gene Therapy Market.

Request Sample Report @https://www.mrrse.com/sample/17781?source=atm

Some key points of Gene Therapy Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Gene Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Gene Therapy Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Gene Therapy market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Gene Therapy market is analyzed and depicted in the report.

The global Gene Therapy market segment by manufacturers include

segmented as follows:

Global Gene Therapy Market, by Product

Global Gene Therapy Market, by Application

Global Gene Therapy Market, by Region

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17781?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Gene Therapy economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/17781?source=atm

Benefits of Purchasing Gene Therapy Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read more here:
COVID-19 impact: Gene Therapy Market 2019 Business Insights,Top Companies,Growth, Market Size Global Market Share, Trends, Outlook, Opportunity and...

Read More...

Gene Therapy For Inherited Genetic Disorders Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

Tuesday, April 28th, 2020

Spark Therapeutics Inc.

Global Gene Therapy For Inherited Genetic Disorders Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=170144&utm_source=LHN&utm_medium=888

Gene Therapy For Inherited Genetic Disorders Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Gene Therapy For Inherited Genetic Disorders industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Gene Therapy For Inherited Genetic Disorders industry.

-> Furthermore, we will help you to identify any crucial trends to predict Gene Therapy For Inherited Genetic Disorders market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Gene Therapy For Inherited Genetic Disorders market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=170144&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Gene Therapy For Inherited Genetic Disorders market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Gene Therapy For Inherited Genetic Disorders market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Gene Therapy For Inherited Genetic Disorders Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Gene Therapy For Inherited Genetic Disorders Market Size, Gene Therapy For Inherited Genetic Disorders Market Growth, Gene Therapy For Inherited Genetic Disorders Market Forecast, Gene Therapy For Inherited Genetic Disorders Market Analysis

Our Trending Reports

Catalyst Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Diabetes Drugs Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more from the original source:
Gene Therapy For Inherited Genetic Disorders Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Read More...

Future Prospects of Plasmid DNA Manufacturing Market by 2026 with Top Key Players Cobra Bio, Richter-Helm, Eurogentec, Cell and Gene Therapy…

Tuesday, April 28th, 2020

Plasmid DNA Manufacturing Market research report is the professional study with the premium insights which includes the size of the business, the ongoing patterns, drivers, dangers, conceivable outcomes and primary segments. The report encompasses the competition landscape entailing share analysis of the key players in the Plasmid DNA Manufacturing market based on their revenues and other significant factors. Report analyzes changing trends and competitive analysis which becomes essential to monitor performance and make critical decisions for growth and development. It also provides market information in terms of development and its capacities.

Get Sample Copy of this report @: https://www.a2zmarketresearch.com/sample?reportId=231682

Leading companies Influencing in this Market are:

Cobra Bio, Richter-Helm, Eurogentec, Cell and Gene Therapy Catapult, VGXI, PlasmidFactory, Kaneka Corporation, Nature Technology Corporation, Waisman Biomanufacturing, FUJIFILM Diosynth Biotechnologies, LakePharma.

In this Plasmid DNA Manufacturing Market research report, the prominent factors driving the advancement of this market were recorded and the business accomplices and end administrators were indulgent. The setup of the business division, examples, and challenges monitoring the market comprehensively are in like manner a bit of this wide examination. Different meetings and social events were driven by the distinguishable pioneers of this industry to get persisting and revived encounters concerned to the market.

The report gathers the essential information including the new strategies for growth of the industry and the potential players of the global Plasmid DNA Manufacturing Market. It enlists the topmost industry player dominating the market along with their contribution to the global market. The report also demonstrates the data in the form of graphs, tables, and figures along with the contacts details and sales of key market players in the global Plasmid DNA Manufacturing Market.

Global Plasmid DNA Manufacturing Market Segmentation:

Segmentation by Type:

HQ Grade Plasmid DNAGMP Grade Plasmid DNANon-GMP Grade Plasmid DNA

Segmentation by Application:

CancersInherited DisordersViral InfectionsOthers

Buy Exclusive Report @: https://www.a2zmarketresearch.com/buy?reportId=231682

Key questions answered in the report include:

Table of Contents

Global Plasmid DNA Manufacturing Market Research Report 2020 2026

Chapter 1 Plasmid DNA Manufacturing Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Plasmid DNA Manufacturing Market Forecast

For more Information! Ask to Experts @: https://www.a2zmarketresearch.com/enquiry?reportId=231682

If you have any special requirements, please let us know and we will offer you the report as you want.

Here is the original post:
Future Prospects of Plasmid DNA Manufacturing Market by 2026 with Top Key Players Cobra Bio, Richter-Helm, Eurogentec, Cell and Gene Therapy...

Read More...

Biotechnology Separation Systems Market: Worldwide Industry to Boost in the Period of 2020-2025 – Express Journal

Monday, April 27th, 2020

The research report on Biotechnology Separation Systems market is a comprehensive analysis of this business space and entails all the key aspects of the industry including net revenue estimates, present renumeration, periodic deliverables, segmental share, market size, and market trends.

A brief assessment of the behavior pattern of the Biotechnology Separation Systems market over the forecast timeline has been cited in the report. Critical parameters such as growth drivers as well the expected growth rate followed during the study period are also documented in the report. It further elaborates on the potential growth aspects and restraints of this industry.

Main highlights of Biotechnology Separation Systems market report:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/65717

Geographical scrutiny of the Biotechnology Separation Systems market:

Biotechnology Separation Systems Market Segmentation: USA, Europe, Japan, China, India, South East Asia.

Key insights presented in the report with respect to the regional outlook:

A thorough analysis of Biotechnology Separation Systems market with respect to the product landscape and application spectrum:

Product landscape:

Product types:

Application landscape:

Other takeaways of Biotechnology Separation Systems market report:

Additional insight on the competitive outlook of the Biotechnology Separation Systems market:

Vendor base of the industry:

Vital parameters which define the competitive landscape of the Biotechnology Separation Systems market:

The study objectives are:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/65717

More:
Biotechnology Separation Systems Market: Worldwide Industry to Boost in the Period of 2020-2025 - Express Journal

Read More...

COVID has set example of how govt is looking at science, its role of facilitation – The Indian Express

Monday, April 27th, 2020

Written by Seema Chishti | New Delhi | Updated: April 26, 2020 11:22:47 am Dr Renu Swarup, Secretary, Department of Biotechnology.

The Department of Biotechnology, under the Ministry of Science And Technology, is the nodal point for all the science-based solutions India is looking for in the battle against COVID-19. Dr Renu Swarup, Secretary, Department of Biotechnology, speaks to The Indian Express on the road ahead.

What role is the Department of Biotechnology (DBT) playing on a day-to-day basis as India wades through this crisis?

Call it day-to-day, hour-to-hour or minute-to-minute. DBT is central to all the science around COVID. Healthcare solutions, diagnostics, vaccines or therapeutics, we are the nodal agency, and this is not just about funding. COVID has set a very clear example of how the government is looking at science and its role of facilitation. We are bringing the countrys scientists on various platforms, institutions, clearing regulatory pathways. We enable coordination. BIRAC (Biotechnology Industry Research Investment Council) has been central to assisting start-ups and connecting them to investors and investments. Now, with the economic crisis, start-ups are facing more challenges and our role has become more critical.

There are 16 proposals under consideration for vaccines, diagnostics and other COVID-related solutions. Could you elaborate on them?

We invited proposals and received about 500 so far, for all aspects of managing diagnostics, therapeutics, vaccines and other resources. There are two proposals which will look at vaccines. We are continuing to screen other proposals. There are 16 in the first tranche that has been cleared. They include plasma therapy models, proposals for vaccines.

Anything more on indigenous testing?

DBT has supported a number of start-ups and research groups. Two of our indigenous start-ups are now approved for manufacturing PCR kits, and in addition, a number of them are developing Rapid Antibody Tests. We have supported a national manufacturing facility at AMTZ (Andhra Pradesh Medtech Zone) Visakhapatnam for kits and ventilators.

There are only two sequences of the virus that India has shared with the worlds database?

We have shared about nine sequences with the world database. Large scale sequencing efforts are starting now. Currently we have no conclusions about what we have in India and if the virus has mutated, but ICMR is looking into it, we are using the global data of thousands of sequences.

Work is happening in Delhi and Hyderabad on genome sequencing of Sars-Cov-2. CCMB Hyderabad and IGIB New Delhi first started working together to study the sequencing?

Those institutes apart, there are six other DBT institutes involved in the work. National Institute of Biomedical Genomics (NIBMG) in Kalyani (near Kolkata), Institute for Stem Cell Science and Regenerative Medicine (inStem), Bengaluru, Institute of Life Sciences, Bhubaneswar (ILS) and Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram (RGCB) are playing a key role along with CCMB in Hyderabad and IGIB in New Delhi in the sequencing of the genome of Sars-Cov-2.

In terms of opening the lockdown, what do you see when you look ahead?

That comes under the remit of the Health Ministry, I have nothing to say.

On a different note, where is Genome India currently?

Collection of samples is not happening at the moment. But all other work in the laboratories, in the planning, computational models, continues as before.

Genome Indias second stage was meant to be collecting samples from the population which are disease-based. Any changes to that plan, a bid to fast-track the disease-based collections now, in the wake of COVID?

No, nothing yet. We will get there as we had planned.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

The Indian Express (P) Ltd

Go here to see the original:
COVID has set example of how govt is looking at science, its role of facilitation - The Indian Express

Read More...

Global Plant Derived Protein Market anticipated grow at a CAGR of xx% over the forecast period 2020-2025 :Medicago, Planet Biotechnology, Ventria…

Monday, April 27th, 2020

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Plant Derived Protein market. The study report covers all the recent developments and innovations in the market for a Plant Derived Protein. There are many government bodies, regulatory associations and universities are extending their help in the form of funds, investments and grants to promote research into the development of products of global Plant Derived Protein market. These activities of researching and funding are fuelling to the development of innovative products.

This study covers following key players:MedicagoPlanet BiotechnologyVentria BiosciencePromoCellKentucky BioprocessingAgrenvecAxol Bioscience

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4555103?utm_source=Pooja

Furthermore, Report provides the deep analysis about the impact of domestic and global players on market, trade regulation, value chain optimization, and opportunities analysis for new present as well as new players, recent developments, strategic market growth analysis, area marketplace expanding, product launches, technological innovations and many more. The study report of global Plant Derived Protein market can be split on the basis of key segments such as product type, application, key companies and key regions. Also the growth of the global Plant Derived Protein market can be projected on the basis of segments and calculation for sales by application and type of the product in terms of volume and value.

In addition, some essential tool which are needed for any market movements are stated in the report. SWOT and value chain rule analysis are studied for the global Plant Derived Protein market report. The global Plant Derived Protein market can be split on the basis of key segments such as type of the product, application, end users, key companies and key regions or countries. Report covers all the major regions and countries on the basis of product type and application. Key regions are mentioned in this report which are likely to grow at the highest CAGR over the forecast period. Report also presents the leading players which are functioning in global Plant Derived Protein market industry. Companies are presented with their company profile and their sales analysis in various regions and countries. Also report offer the growth strategies being implemented by these major large and small market players.

Access Complete Report @ https://www.orbisresearch.com/reports/index/global-plant-derived-protein-market-growth-2020-2025?utm_source=Pooja

Market segment by Type, the product can be split into Protein PolymersTherapeutic ProteinsCell Culture Functional ProteinsOthersMarket segment by Application, split into Biopharmaceutical CompanyAcademic & Research InstituteContract Research OrganizationOthers

This report provides customers with market statistics by studying the historic data and current status of the market. Also report ensures the success of user by providing comprehensive study of the market. The database is constantly updated in order to fulfil the demands of the clients. Thus report consist of a comprehensive variety of information from key industry. Report offers in depth insight on global products, industries and market trends for the customers.

Some TOC Points:

1 Industry Overview of Plant Derived Protein2 Major Manufacturers Analysis of Plant Derived Protein3 Global Price, Sales and Revenue Analysis of Plant Derived Protein by Regions, Manufacturers, Types and ApplicationsContinued

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4555103?utm_source=Pooja

Some TOC Points:1 Scope of the Report2 Executive Summary3 Global Plant Derived Protein by Company4 Plant Derived Protein by RegionsContinued

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Continued here:
Global Plant Derived Protein Market anticipated grow at a CAGR of xx% over the forecast period 2020-2025 :Medicago, Planet Biotechnology, Ventria...

Read More...

Introducing iNtRON Biotechnology (KOSDAQ:048530), The Stock That Dropped 34% In The Last Five Years – Simply Wall St

Monday, April 27th, 2020

iNtRON Biotechnology, Inc. (KOSDAQ:048530) shareholders should be happy to see the share price up 13% in the last month. But over the last half decade, the stock has not performed well. In fact, the share price is down 34%, which falls well short of the return you could get by buying an index fund.

View our latest analysis for iNtRON Biotechnology

Given that iNtRON Biotechnology didnt make a profit in the last twelve months, well focus on revenue growth to form a quick view of its business development. When a company doesnt make profits, wed generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

While the broader market lost about 11% in the twelve months, iNtRON Biotechnology shareholders did even worse, losing 33%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case theres a good opportunity. Unfortunately, last years performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8.1% over the last half decade. We realise that Baron Rothschild has said investors should buy when there is blood on the streets, but we caution that investors should first be sure they are buying a high quality business. Its always interesting to track share price performance over the longer term. But to understand iNtRON Biotechnology better, we need to consider many other factors. Take risks, for example iNtRON Biotechnology has 2 warning signs we think you should be aware of.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on KR exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the article here:
Introducing iNtRON Biotechnology (KOSDAQ:048530), The Stock That Dropped 34% In The Last Five Years - Simply Wall St

Read More...

Stem Cell Biology and Its Complications – The New York Times

Monday, April 27th, 2020

The renewed debate over embryonic stem cells highlights the advances and complications that have arisen in the field since its controversial beginnings.

The cells are a sort of blank slate, plucked from human embryos just a few days after fertilization. They tantalize scientists because they could in theory turn into any of the bodys 200 mature cell types, from blood to brain to liver to heart. They could be used to study and treat diseases and to study the basic biology of what determines a cells destiny why a heart cell becomes a heart cell, for example, instead of a brain cell.

The problem is their origin human embryos. In order to get stem cells, embryos must be destroyed. It is this fact that led to the court ruling on Monday blocking most federal financing for embryonic stem cell research.

The scientist who isolated human embryonic stem cells in 1998 struggled with this dilemma, consulting ethicists before proceeding. But in the end, the scientist, Dr. James Thomson of the University of Wisconsin, decided to go ahead because the embryos were from fertility clinics and were going to be destroyed anyway. And, he reasoned, the work could greatly benefit humanity.

Yet despite the high hopes for embryonic stem cells, progress has been slow so far there are no treatments with the cells. The Food and Drug Administration just approved the first clinical study, a dose and safety test, of human embryonic stem cells to treat spinal cord injuries.

All along, though, scientists wondered if they could sidestep the ethical debate by creating embryonic stem cells without the embryos. Every cell has the same DNA. A heart cell is different from a liver cell because it uses different genes. But all the genes to make a liver cell, or any other cell, are there in the cell. The liver genes are masked in a heart cell and vice versa. Why cant scientists find a way to unmask all of a cells genes and turn it directly into a stem cell without using an embryo?

A few years ago, two groups of researchers one led by Dr. Thomson did just that. They discovered that all they had to do was add four genes and a cell would reprogram itself back to its original state when it was a stem cell in an embryo. Like an embryonic stem cell, that reprogrammed cell seemed to be able to then turn into the many kinds of specialized cells in the body, an ability called pluripotent.

What has happened since that discovery, scientists say, is that stem cell biology turned out to be more complicated than they anticipated. Besides the stem cells from embryos, there are so-called adult stem cells found in all tissues but with limited potential because they can only turn into cells from their tissue of origin. And there are these newer cells made by reprogramming mature cells.

Now researchers are trying to figure out whether stem cells made by this reprogramming process really are the same as ones taken from embryos. Some say they found subtle differences between these cells, known as induced pluripotent stem cells, or I.P.S.C.s, and embryonic stem cells. Others are not so sure.

They say they need embryonic stem cells as a basis of comparison, a gold standard to see if the newer reprogrammed cells are as good.

We are not at the stage where you will find many investigators saying, We dont need embryonic stem cells because I.P. cells are the same, said Dr. Timothy Kamp, a stem cell researcher and professor of medicine at the University of Wisconsin School of Medicine and Public Health. We dont know that yet.

One complication is that different labs use different methods to obtain the reprogrammed cells and to study them, Dr. Kamp said. As a result, he said, not all I.P. cells are the same.

John Gearhart, director of the Institute for Regenerative Medicine at the University of Pennsylvania, and one of the first to isolate human embryonic stem cells, said some investigators ended up with reprogrammed cells that will have little utility. They are only partly reprogrammed, he explains.

One worries about how safe and effective they are going to be if they are ever used in therapies, Dr. Gearhart said.

Dr. George Q. Daley, a stem cell researcher at Childrens Hospital in Boston, saw subtle differences in a recent study. When he just compared the two types of cells side by side with molecular tests, they looked identical. Then he tried turning them into various types of mature cells and comparing the results.

Dr. Daley published a paper in March, in Nature Biotechnology, reporting that mouse I.P.S.C.s from different tissues remembered, in a sense, where they came from. He has a similar paper under review showing the same effect with human induced pluripotent stem cells.

In the mouse study, it was harder to get pluripotent mouse cells derived from a skin cell, for example, to turn into blood cells than it was to get pluripotent stem cells made from blood cells to turn into blood cells.

They tended to remember their tissue of origin, Dr. Daley said.

Researchers need to find ways to make the cells forget where they came from, he said.

Rudolf Jaenisch, a stem cell researcher and biology professor at M.I.T., said he was not certain there were meaningful differences between human embryonic stem cells and human induced pluripotent cells.

But to answer that question will require the use of embryonic stem cells for comparisons, Dr. Jaenisch said.

Things are very much in flux, he said. We will probably need human embryonic stem cells for a while. And then we probably will not need them anymore.

Here is the original post:
Stem Cell Biology and Its Complications - The New York Times

Read More...

Sallie Permar: Who Are Your Trusted Sources on COVID-19? – Duke Today

Monday, April 27th, 2020

As the COVID-19 pandemic continues, the question of where to turn for solid information has never been more important.

Many Duke experts are being approached now for their expertise and insight. But where do they turn for guidance and the latest information? In this ongoing series, Duke Today asks Duke experts to share their preferred sources.

Dr. Sallie Permar is a physician scientist who focuses on prevention and treatment of neonatal viral infections. A professor of immunology, pathology, pediatrics, molecular genetics and microbiology and associate dean for physician-scientist development, she recently wrote about the effect of the pandemic on medical research.

To stay abreast of how the infectious diseases field is responding to the novel coronavirus, she consults a mix of websites, podcasts and social media.

This Week in Virology, hosted by Vincent Racaniello and fellow virologists, has featured recent guest hosts who are stars of COVID-19 research, such as Drs. Daniel Griffin, Ralph Baric, Mark Denison, Stanley Perlman and Christian Drosten.

Immune, hosted by immunologists Cindy Leifer, Stephanie Langel, Vincent Racaniello, carried a recent two-part series on COVID-19 immunology with Dr. Brianne Barker that was especially compelling.

I also listen to COVID-19: Commonsense Conversations on the Coronavirus Pandemic, with host Dr. Ted OConnell, a family physician and writer.

For the latest on numbers by region, I check Johns Hopkins Universitys COVID-19 map.

COVID-19 guidelines can be found on the Centers for Disease Control website.

For the latest on viral sequence dynamics, I check gisaid.org.

For recent COVID-19 research reports, I consult bioxiv.org and medrxiv.org. The Twitter sources below provide real-time critical reviews of the newly posted manuscripts.

For the latest on epidemiology and case series reports, I consult: - the CDC Morbidity and Mortality Weekly Report and - World Health Organization situation reports.

And for compilations of the latest research I check: - Duke Pharmacist Elizabeth Dodds-Ashleys Daily Digest. - The American Association of Medical Colleges Novel Coronavirus Update by chief scientific officer and former Duke faculty member Dr. Ross McKinney. - Publons compilation of latest research manuscripts, which includes some crowd-sourced reviews.

Finally, great sources to follow on Twitter include:@NIAIDNews; @CEPIvaccines;NIH Vaccine Research Center scientist Kizzmekia Corbett (@KizzyPhD);The laboratory of UNC-Chapel Hills Dr. Ralph Baric (@Baric_Lab);The laboratory of Vanderbilt Universitys Dr. Mark Denison (@Denisonlab);Florian Krammer, an immunologist who is developing antibody assays (@florian_krammer); Virologists Dr. Benhur Lee (@VirusWhisperer) and Angela Rasmussen (@angie_rasmussen);COVID-19 drug developer Timothy Sheahan (@timothysheahan);David Martinez, a former Ph.D. student who is now testing vaccine and therapeutic antibodies in the lab of Ralph Baric (@David_RMartinez).

View post:
Sallie Permar: Who Are Your Trusted Sources on COVID-19? - Duke Today

Read More...

A gene that could unlock the mysteries of COVID-19 – ModernHealthcare.com

Monday, April 27th, 2020

The team's results, posted as a preprint in BioRxiv earlier this month, proposed a handful of ACE2 variants suspected of boosting SARS-CoV-2 binding and, potentially, host susceptibility, along with several variants predicted to dial down ACE2 interactions with the viral spike protein that may be protective.

"What we can conclude is that this new virus has evolved new modality to interact with the ACE2 receptor," Jura noted. "Unfortunately, it seems like there are polymorphisms in the human population that will make some individuals more susceptible to binding this virus because these mutations are enhancing this unique part of the interface."

Seshagiri noted that such insights might make it possible to design potential therapeutic versions of ACE2 that are particularly adept at binding coronavirus spike proteins, thereby preventing the viruses from interacting with an individual's own ACE2 receptors, for example.

In a recent Cell paper, a team from Sweden, Spain, Austria, and Canada proposed its own strategy for engineering soluble, clinical-grade forms of the human ACE2 protein that appeared to dial down early-stage infections by SARS-CoV-2 in otherwise susceptible cell types.

"We are not the first to come up with the idea of saying ACE2 could be a therapeutic," he said, though he suggested that engineering soluble forms of the receptors protein that bind well to SARS-CoV-2 may serve as a strategy for "future proofing" against the emergence of these and other related viruses down the road.

The researchers plan to profile ACE2 polymorphisms in still more human samples for the final version of the study, which will likely be submitted for peer review in the coming weeks, Seshagiri said.

He and MedGenome CEO Rayman Mathoda noted that the diagnostic company, which is active in India and other emerging markets, is also a founding member of a GenomeAsia 100K project.

"We've made a very intentional effort to build on a data-focused set of efforts, where we take our proprietary data as we grow, but build in other data source," Mathoda said.

The investigators are not alone in attempting to establish a baseline understanding of ACE2 variation across and within populations.

At the University of Siena in northern Italy, Alessandra Renieri and her colleagues have been delving into ACE2 genetic variation using available exome sequences for some 7,000 healthy participants in the Network of Italian Genomes project. As they reported in a preprint posted to MedRxiv in early April, the investigators saw significant variation in ACE2 in that retrospective dataset, including both common and rare, missense variants predicted to influence the protein's stability and its interactions with the coronavirus viral spike.

"There is pretty wide genetic variability," Renieri said. "There are both polymorphisms, so variants found in a percentage of the population, and there are also rare variants a lot of rare variants."

It may be possible for the individual centers participating in the Network of Italian Genomes to recontact individuals in the future to try to find out who became infected with SARS-CoV-2 and to assess ACE2 variation alongside clinical outcomes, Renieri noted, though she cautioned that "ACE2 is just one of the many genes that could be involved."

For the reCOVID project, members of the team are seeking funding through the European Commission's Innovative Medicines Initiative IMI2 call for proposals to do functional analyses on ACE2 and other genes, for example, in the hopes of developing candidate therapeutics.

Renieri is also part of a team that been working since mid-March to prospectively collect samples from 2,000 COVID-19 patients at least 21 different hospitals in Italy as part of the GEN-COVID study, part of the COVID-19 Host Genetics Initiative.

For that project, researchers in Italy will use whole-exome sequencing to assess patient samples collected in conjunction with very detailed clinical information, she explained, while collaborators in Finland will genotype the samples for a related genome-wide association study.

See more here:
A gene that could unlock the mysteries of COVID-19 - ModernHealthcare.com

Read More...

Book review: ‘The Future is Faster Than You Think’ – Bowling Green Daily News

Monday, April 27th, 2020

The Future is Faster Than You Think: How Converging Technologies Are Transforming Business, Industries and Our Lives by Peter H. Diamandis and Steven Kotler. New York: Simon & Schuster. 2020, 384 pages, $20 (hardcover).

There is little doubt that the decade to come will be filled with radical breakthroughs and world-changing surprises, Peter H. Diamandis and Steven Kotler observe near the beginning of The Future is Faster Than You Think: How Converging Technologies Are Transforming Business, Industries and Our Lives, their exciting new treatise on what lies just around the corner and the impact it will have on everything.

As the chapters ahead make very clear, every major industry on our planet is about to be completely reimagined, they continue. For entrepreneurs, for innovators, for leaders, for anyone sufficiently nimble and adventurous, the opportunities will be incredible. It will be both a future thats faster than you think and arguably the greatest display of imagination rendered visible the world has yet seen. Welcome to an era of extraordinary.

As someone who has read a fair amount on what various thinkers have written about the wonders and pitfalls the future holds, I tend to be somewhat skeptical of these kinds of hyperbolic proclamations. In the present case, however, after making my way through this exquisite manuscript on where we currently find ourselves as a species, I have come to the conclusion their assessment is justified. We are indeed on the cusp of a revolution that will fundamentally change the world and how we function in it.

As might be expected given the nature of the subject matter, the book is exceptionally well-researched, with 76 pages of source notes at the conclusion of the foreword, 14 chapters and afterword that comprise the main text. Structurally, the content is arranged in three major sections: Part One, The Power of Convergence, consists of the first four chapters; Part Two, The Rebirth of Everything, is made up of the next eight chapters; and Part Three, The Faster Future, finishes out the narrative with chapters 13 and 14.

From my vantage point, Part Two constitutes the real meat and potatoes of their phenomenally insightful and intrinsically thought-provoking prose. The entire section is an interconnected description of what lies just over the horizon, as noted by the cascading chapters: The Future of Shopping, The Future of Advertising, The Future of Entertainment, The Future of Education, The Future of Healthcare, The Future of Longevity, The Future of Insurance, Finance, and Real Estate and The Future of Food. Embedded in these themes is an overarching nod to the future of work, something we all have a vested interest in from a more personal perspective.

As is usually the case with this kind of book, I was naturally drawn to how Diamandis and Kotler envision the tremendous technological innovations occurring at a breakneck pace and transforming education at all levels. Although I was a little apprehensive as I made my way through many of their arguments and the evidence they provided to support them, I was nonetheless encouraged by the optimistic tone that was unmistakable throughout their thesis.

Batch processing children is both an industrial hangover and an educational disaster because of basic biology, they explain in The Future of Education, the eighth chapter and one of my personal favorites for reasons previously indicated. Everyone is wired differently. Some of this is nature, some nurture, but the end result is the same: Were individuals, and theres no standard set of engaging experiences that can maximize learning for all.

But converging technology offers a host of new solutions to the challenges of quality and quantity, the authors continue a little later. Every technology thats currently making an impact on entertainment is doing double duty in education, meaning, as well see in a moment, one-size-fits-all is no match for the app store.

Lets just say I was not disappointed by the portrait they painted of the next phase in educations quickly-evolving manifest destiny.

Diamandis is founder and executive chairman of the XPRIZE, executive founder of Singularity University and the co-founder of Human Longevity Inc., Celularity and Bold Capital Partners. He has degrees in molecular genetics and aerospace engineering from MIT as well as an MD from Harvard Medical School. The founder of more than 20 high-tech companies, Fortune magazine named him one of the Worlds 50 Greatest Leaders in 2014. Kotler is founder and director of the Flow Research Collective as well as a best-selling author and award-winning journalist. His work has appeared in Time, The New York Times Magazine, The Atlantic, Wired and Forbes. His previous books include Stealing Fire, The Rise of Superman, Tomorrowland and Last Tango in Cyberspace.

In the final analysis, Diamandis and Kotler are realistic yet guardedly optimistic about the potential future thats within our grasp. They are not nave to the dangers that lie ahead, but they refuse to be paralyzed by them. In one sense, I interpreted their tome as a call to action an admonition to be more purposeful and rational in how we use the amazing tools we have at our disposal. Keeping the glass half full will take our collective commitment.

To be clear, there will still be terrorism, war and murder, they concede in the afterword. Dictatorship and disease wont go away. But the world will quietly continue to get better. The goal here isnt about creating a life of luxury, but rather a life of possibility. Thanks to the forces of convergence, the technological advances needed for that world of abundance are coming at an ever-increasing pace. Of course, creating that world wont happen automatically. It will still require the largest cooperative effort in history. And this brings us to our final question: What, exactly, are you waiting for?

I see that as a challenge none of us can afford to ignore. This was a very intriguing, sobering, enlightening and ultimately uplifting journey; highly recommended.

Reviewed by Aaron W. Hughey, Department of Counseling and Student Affairs, Western Kentucky University.

Read this article:
Book review: 'The Future is Faster Than You Think' - Bowling Green Daily News

Read More...

The Indian academic making the world look at flavours and food in a fresh way – The National

Monday, April 27th, 2020

If you are a foodie and love experimenting with flavours, how does a shrimp and egg salad sound for lunch? Or a tender juicy steak, just out of the oven, topped with a dollop of cheddar or Camembert, to be precise. And did you know mushrooms go smashingly well with nearly every common fruit, from apples to apricots and even coconut?

These food pairings may sound unappealing or at least unusual to most people, but Dr Ganesh Bagler of the Indraprastha Institute of Information Technology, New Delhi, says otherwise and he has the data and research to show for it.

Can we encode the intelligence of a chef into a computer, or can a computer fool a chef into thinking a recipe is real?

Akshay Malhotra

The computational gastronomy expert has taken the food and drink industry by storm with his ground-breaking work on flavour molecules and its corresponding database, FlavorDB.

His laboratory has also developed DietRX, an archive of nearly 2,000 foods, their chemical and genetic compositions, and their effect on health, which can enable culinary and drug interventions. (Ayurvedic diets are a historically important example of the belief in healing via appropriate foods.)

The power of data and food together is magic, says Bagler.

Already, chefs such as Garima Arora of Restaurant Gaa in Bangkok, are using Baglers research to fuel their own food experiments. What I find amazing about Baglers research is that his approach actually enables us to know exactly what makes up a cuisine the things that make Indian cuisine Indian, Arora, who is the first Indian woman with a Michelin star to her name, tells The National.

Once we have that knowledge, we can truly get to the main taste of a cuisine, which will help us do away with the flavours and ingredients we dont need.

Baglers work is also critical to Aroras Food Forward India, a non-profit initiative that aims to broaden the narrative around Indian food. It fits into the framework by being a forward-thinking initiative, one that serves the purpose of codifying a cuisine, and identifying, quantitatively, its identity, says project manager Matylda Grzelak.

Bagler, who is now considered the pioneer of computational gastronomy in India, credits curiosity for his success. Having studied various subjects from graduation through to postdoctoral studies quantum mechanics, computer science, computational biology, computational neuroscience and molecular genetics Bagler returned to India in 2010 following a stint at Berlins Max Planck Institute for Molecular Genetics.

He joined the CSIR-Institute of Himalayan Bioresource Technology at Palampur as a researcher, and worked on medicinal plants in the western Himalayas, and on diseases such as cancer and asthma. But it was not enough.

I like to explain things; Im a teacher, he says. This led him to the prestigious Indian Institute of Technology Jodhpur and finally IIIT-Delhi.

Bagler's foray into gastronomy happened when he came across a 2011 paper that took off from British chef Heston Blumenthals food-pairing hypothesis: foods that share flavour molecules will taste better together than those that do not.

For example, chocolate and blue cheese taste great together because they share 73 flavours (Blumenthals interest was piqued when he paired white chocolate and caviar, and hit the right notes). This led to companies such as Foodpairing, which present thousands of combinations of ingredients for chefs to experiment with.

Historically speaking, dishes have evolved over millennia from single-ingredient meals to complex ones, says Bagler. Cooking techniques and creative expression aside, why are some ingredients used together and others not? This was one of the critical questions that led Bagler to expand his research. Food science has been around, but it explored aspects such as the shelf life of foods or how to enhance sensory enjoyment. Now, people are looking at food from a data perspective.

What Bagler did differently was focus on Indian food, which he found is different from other cuisines because of the spices. Breaking down a collection of the late, celebrated Indian chef Tarla Dalals recipes, Bagler realised that spices form the basis of food-pairing in Indian cuisine. Having divided various foods into 26 categories vegetables, dairy, lentils, meats, etc he saw that mixing up items across all other sections did not cause too much of a shift in flavour, but when the spices were shuffled, the taste changed entirely.

Spices are the molecular fulcrum of Indian food

Dr Ganesh Bagler

For example, you could replace spinach with fenugreek leaves in palak paneer and there would not be much change in the dish, but if you replaced turmeric with cinnamon, the very essence of the preparation alters. Spices are the molecular fulcrum of Indian food, says Bagler.

In 2015, Bagler and his team of researchers sent this study to international science journals, which uploaded it to an open server where it was picked up by MIT Tech Review. This changed Baglers life. I only understood the academic value of this work, not its futuristic value, he says. It took me a year to understand that this had led to the creation of a new field of study, and now, over the past five years, Ive been developing the foundations of this area.

From 2,543 of Dalals recipes to nearly 158,000 global recipes, Baglers database has expanded exponentially. Not only is the data free to access on various websites and apps, but the information is also provided in excruciating detail, from the scientific names of elements to a comprehensive flavour network, possible pairings and health benefits. Bagler is also due to launch RecipeDB at a conference postponed amid the Covid-19 crisis where a massive collection of structured recipes will be available for everyone from chefs and cooking enthusiasts, to restaurateurs, multinationals and scientific organisations to use freely.

People know food technology, but they do not know about flavour technology, says Deepika Nadiminti, a flavourist at Mane India, which develops flavours for the dairy, confectionery and drinks industries. Baglers database is an all-in-one resource, where we can identify everything from flavour molecules to physical and chemical properties, and experiment easily, she says.

While Bagler consults for institutions such as the Indian Institute of Hotel Management and Symbiosis School of Culinary Arts, as well as a range of multinationals, chefs also swear by his research, which has significantly reduced time spent on developing new dishes, says Akshay Malhotra, a chef, food consultant and former student of the Culinary Institute of America.

FlavorDB will help us to understand the science behind Indian food, and it is only the beginning of how artificial intelligence will influence the food industry, he says.

This aspect is also key to Baglers future experiments. Can we encode the intelligence of a chef into a computer, or can a computer fool a chef into thinking a recipe is real? says Malhotra.

Can human creativity, which is at the heart of cooking, be reproduced using AI? It remains to be seen. For now, Malhotras observations pertain to FlavorDB complementing chefs instincts about pairing ingredients.

As celebrity chefs Manjit Gill and Akshraj Jodha describe Bagler's work, he is successfully quantifying the knowledge that, until now, was only intuitively available to a cook and everyone from chefs and diners to scientists will benefit from it.

Updated: April 25, 2020 04:57 PM

Go here to read the rest:
The Indian academic making the world look at flavours and food in a fresh way - The National

Read More...

Creighton’s Hereditary Cancer Center makes groundbreaking discoveries in cancer research – Omaha World-Herald

Monday, April 27th, 2020

Its difficult for Robin Farias-Eisner, M.D., Ph.D., to condense decades of cancer research into a single conversation. But recent developments call for brevity.

Sitting in his office on the second floor of the Hixson-Lied Science Building, Farias-Eisner, the newest director of Creighton Universitys Hereditary Cancer Center, explains how he and a team of researchers have discovered a new drug with the potential to treat a broad array of illnesses, including ovarian cancer, colon cancer, macular degeneration, heart disease and more.

It would be hard to overstate it, Farias-Eisner says of the potential impact of the find.

The research is one example of how the Hereditary Cancer Center is fulfilling its mission to pursue comprehensive research on all types of cancer. Established in 1984, the center is particularly devoted to cancer prevention through identification of hereditary cancer syndromes.

The center was founded by legendary cancer researcher Henry Lynch, M.D., a Creighton professor and pioneer in the field of cancer genetics. Prior to Lynchs research, prevailing medical thought held that cancer was primarily caused by environmental factors.

Through what doctors today call shoe-leather epidemiology, Lynch tracked down and interviewed cancer patients about their family histories, tracing the inheritance patterns of certain cancers through multiple generations. Researchers now estimate between 5% and 10% of cancers are inherited, according to the National Cancer Institute.

Lynch died at age 94 in June 2019. In July, the University named Farias-Eisner the new head of the Hereditary Cancer Center.

Farias-Eisner came to Creighton from the University of California, Los Angeles. There, as a surgeon-scientist, he earned a Ph.D. in molecular biology and ran his own laboratory specializing in womens cancer research.

My ultimate objective was to take care of women who had cancer, particularly gynecological cancers, because I felt that was an underserved population, Farias-Eisner says.

Through his lab work, Farias-Eisner and co-inventor, UCLAs Srinivasa Reddy, Ph.D., and a team of researchers identified a group of proteins that serve as early identifiers of ovarian cancer. The research led to the development of OVA1, a blood test that is currently being used worldwide to diagnose the disease.

Building on this work, Farias-Eisner, Reddy and a team of researchers developed HM-10/10, an artificial peptide that has been shown to be effective in inhibiting tumor growth in ovarian and colorectal cancers in mice.

In January, a paper detailing the research, Bovine HDL and Dual Doman HDL-Mimetic Peptides Inhibit Tumor Development in Mice was published as the featured article in the Journal of Cancer Research and Therapeutic Oncology. In addition to Farias-Eisner, the paper includes Holly Stessman, Ph.D., assistant professorin the Department of Pharmacology in Creightons School of Medicine.

This is a story of taking discoveries from the research bench and serendipitously arriving at a novel drug for use at the patients bedside, Farias-Eisner says.

The drug, Farias-Eisner says, has the potential to treat other pro-inflammatory diseases, a category which includes macular degeneration, heart disease, Alzheimers disease and endometriosis, among other clinically devastating diseases.

Prior to publishing on its effectiveness as a cancer treatment, Farias-Eisner and the team published another paper in the International Journal of Molecular Sciences showing HM-10/10s potential to treat retinal disease (e.g. macular degeneration).

The reason we wanted to publish in these two areas is to demonstrate the uniqueness of the drug and its clinical applications, Farias-Eisner says. Now that we have these two published papers, we can move toward clinical trials.

Creighton University offers a top-ranked education in the Jesuit, Catholic tradition and a welcoming, supportive environment to a diverse community of educators, professionals and support staff.Read moreabout the university, and connect with Creighton onFacebook,TwitterandInstagram.

Originally posted here:
Creighton's Hereditary Cancer Center makes groundbreaking discoveries in cancer research - Omaha World-Herald

Read More...

SHS grad involved in COVID-19 testing – SouthCoastToday.com

Monday, April 27th, 2020

SOMERSET When the Westborough based Integrated Genetics asked if any of its employees wanted to relocate to New Jersey for six weeks to do COVID-19 testing, Andrew Lanneville volunteered to go. He said it is a small contribution he can make to help during the coronavirus pandemic, but if he is needed, he is happy he can help.

"I wanted to do it," Lanneville said. "My family and friends and girlfriend have been very supportive of it. My employer has been gracious, always checking in on me, and the people down here are very grateful."

Integrated Genetics is a subsidiary of LabCorp Specialty Training Group. Lanneville, a 2008 graduate of Somerset High School, is a molecular biologist for Integrated Genetics. He is testing DNA samples from the sickest people in hospitals to determine whether they have COVID-19 or not. Lanneville said there are a lot of talented people from different places in the country who are working in the lab.

"People are here because they want to do their part, do what they can," Lanneville said in a telephone interview with The Spectator last Monday. "If they want to run molecular assays and DNA testing, I'm happy to do it and other people are happy to do it, as well."

Lanneville said 10,000 tests per day for COVID-19 were being done in the district in New Jersey where he was working. Last week, he said they were beginning a second method of testing that will take some of the burden off the instrumentation they are using so that they could double the amount of tests they were doing. He said the DNA samples don't just come from New Jersey, but also from New York and other places in the country.

In an article in The New York Times on April 13, the paper reported that the backlog for coronavirus testing in New Jersey was getting worse. At that time, the Times reported that New Jersey had conducted 115,000 tests, about one for every 75 residents. The newspaper article reported that the tests are a critical tool in measuring the disease's spread and a requirement for certain forms of treatment, yet they remain hard to get, and many people are actively discouraged from trying to get the tests. The article said that initially, the backlog was happening because there was not enough test kits, but said now there are not enough swabs and nurses. New Jersey has the second highest caseload of coronavirus cases in the country.

Another article in The New York Times on April 15 reported that, "The American Clinical Laboratory Association, a trade group representing large diagnostic companies like LabCorp and Quest, has recently reported a dip in the daily testing volumes of its members. On Monday, its members processed 43,000 tests, the lowest number since March 20. At one point in early April, members were processing more than 100,000 a day."

Lanneville said the people in the lab do not see the people who the samples come from. He said they don't even know their names. Each sample has a bar code to identify it to protect the identity of the person.

Lanneville said there are two types of testing done to determine if people have COVID-19. One is an antibodies test, which his company does not do. He said that test attempts to detect changes in immnune cells that are preparing to fight the virus. Lanneville said the problem with antibodies testing is that someone may be infected with the virus, but their body may not have changed to fight it yet, so it is possible to get false negatives. The other test, which his company uses, is a DNA test that directly detects the virus. It is called Polymerase Chain Reaction testing, which has been around since 1985. Lanneville said the test is based on a preliminary chain reaction that involves the COVID-19 being copied millions of times, if it is present in the sample from someone's body. He said the test takes a few hours to do.

"It's a little more involved," Lanneville said of the PCR test. "It's a little more technical. It takes a little more time."

Lanneville said sometimes the instrumentation being used to run the tests breaks down because it is being used so much to run samples.

Lanneville said the DNA test is more accurate than the antibodies test. He said reagants, that are like the on ramps and off ramps, are added to the DNA highway. The enzyme polymerase is the car that goes on and off the highway that replicates the viral DNA millions of times to confirm it's present. Lanneville said a process is gone through that can replicate viral DNA many times over if it is in the sample from the person's body. He said if there was COVID-19 in the person's body, there will be millions of copies of it. If the person did not have COVID-19, he said no copies are produced.

"It' very robust," Lanneville said of the PCR test. "It is very obvious who is positive for this virus and who is negative for it."

When Lanneville was interviewed by The Spectator over the phone last Monday, he had been at the lab in New Jersey for three weeks. He said when he first got to the lab, 30 to 32 percent of samples were testing positive for COVID-19, but those numbers rose to 35 to 36 percent. Lanneville said he does not think the increase is alarming because he says physicians are getting a better eye for who has symptoms of COVID-19, the flu or allergies.

Lanneville has worked in clinical laboratories for the last six years. He runs experiments that involve many people. Lanneville has a lot of experience running genetics based tests to see if there is a risk of passing on cystic fibrosis or other types of conditions to family members. He said his clients want more information about how that could affect the health of a child that is going to be born.

Lanneville said the COVID-10 DNA-based testing is a little different than what he usually does in terms of the setting and the patients, but he said the technology, equipment and theories behind the test are the same. He has been working 70 hours a week in the lab in New Jersey.

At Somerset High School, where he took Advanced Placement classes, Lanneville was involved in tennis, soccer, cross country and Model United Nations. After graduating from Somerset High School, Lanneville studied biology and economics at the University of Massachusetts at Amherst. While he is working, he is attending Boston College part-time to study business.

Asked about the risk of being infected with COVID-19 during the testing, Lanneville said, "At this point we are wearing surgical masks and protective face shields, along with gloves and labcoats. In addition, all COVID-19 samples (potentially positive or negative) are manipulated in a fume hood which has a negative pressure to essentially 'pull' the air out of the hood and also has a protective glass shield. There are some times when the samples are briefly exposed to the open air, when loading onto laboratory equipment, and there is no solution other than to minimize that time as much as possible."

"We have heard that another company performing testing in the area now has three technologists with COVID. There is some speculation that it may be due to the fact that the lab in question was manipulating samples in an open air environment. With all of the PPE needed at our disposal, I feel confident that risk of transmission is quite low. Honestly, I may have a higher likelihood of getting it from someone in the public areas of this building, outside of the lab, or the doorways of the hotel I'm staying at."

See more here:
SHS grad involved in COVID-19 testing - SouthCoastToday.com

Read More...

Mt. Sinai Hospital’s Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From FDA – The Jewish Voice

Monday, April 27th, 2020

Edited by: JV Staff

Several days ago, the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories received emergency use authorization from the U.S. Food and Drug Administration (FDA) for an antibody test that was developed, validated, and launched at Mount Sinai by a team of internationally renowned researchers and clinicians of the Icahn School of Medicine at Mount Sinai. This test detects the presence or absence of antibodies to SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) and importantly, may also be used to identify positive specimens with an antibody titer (level) up to a dilution of 1:2880 for the identification of individuals with higher antibody titers.

This important regulatory authorization reflects the success of a truly translational medical effort by our basic scientists, pathologists, and clinicians who have risen to the occasion and combined their unparalleled expertise in a way that will help the community at large as we fight this terrible disease, said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and President for Academic Affairs of the Mount Sinai Health System.

A research team led by Florian Krammer, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, began working on the serologic test in January 2020, before COVID-19 had been seen in the United States. To make the test, the researchers used animal cells to produce copies of the telltale spike protein that is present on the surface of SARS-CoV-2. That protein is highly immunogenic, meaning that peoples immune cells see it and start making antibodies that can lock onto it. The test involves exposing a sample of blood to bits of the spike protein. If the test lights up, it means that person has the antibodies. Similar to the most commonly used tests for other viruses, such as hepatitis B, this test shows whether a persons immune system has come into contact with SARS-CoV-2.

Our test can pick up the bodys response to infection, in some cases as early as three days post-symptom onset, and is highly specific and sensitive, says Dr. Krammer. We have shared the toolkit needed to set up the test with more than 200 research laboratories worldwide to help mitigate this global crisis.

Once the research test had been developed in Dr. Krammers microbiology lab, Mount Sinais pathology and laboratory medicine experts were able to quickly transfer the technology to The Mount Sinai Hospitals Clinical Laboratories, which are certified by the Clinical Laboratory Improvement Amendments and accredited by the College of American Pathologists, signifying that the laboratory meets or exceeds industry standards for clinical laboratory testing. In this regulated laboratory environment, under the guidance of Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine, the test was validated.

Our microbiology colleagues generated great science and tools that were brought from the research lab into the clinical space to implement robust and compliant diagnostic tests with great specificity and sensitivity so that we can better care for our patients, says Dr. Cordon-Cardo. We are grateful to the FDA for granting this expanded authorization so that we can deploy this vital test to the community at large.

Under the leadership of David L. Reich, MD, President of The Mount Sinai Hospital, and Judith A. Aberg, MD, Chief of the Division of Infectious Diseases and Immunology in the Department of Medicine, The Mount Sinai Hospital became among the very first in the United States to initiate a convalescent plasma program on Saturday, March 28.

The exchange of ideas between clinicians and scientists and our intense drive to innovate is the catalyst that led to this achievement, says Dr. Reich. Mount Sinai will continue to advance the science and medicine in the fight against COVID-19.

Serologic testing for COVID-19 is a critical tool for helping us to understand the nature of the disease within our communities., says Erik Lium, PhD, Executive Vice President and Chief Commercial Innovation Officer of the Mount Sinai Health System. We continue to broadly partner this technology with industry, recognizing the need to scale serologic testing effectively.

Mount Sinais rich history and leadership in the fields of pathology, microbiology, and immunology helped to make this discovery and clinical application possible. From its beginnings in 1893, the Mount Sinai Department of Pathology, Molecular and Cell-Based Medicine has been a leader in the field. In addition to delivering more personalized pathology services to patients, Mount Sinai was the first major medical center to establish a fully integrated pathology department combining the various arms of testinganatomical, clinical, molecular/genetic, and cytologicalunder a single umbrella and now has the second largest department of its type in the nation.

The Department of Microbiology is led by internationally renowned microbiologist Peter Palese, PhD, who pioneered the field of reverse genetics for negative-strand RNA viruses, a revolutionary technique that is crucial for the study of the structure/function relationships of viral genes, for the investigation of viral pathogenicity, and for the development and manufacture of novel vaccines. It also has significant implications in understanding and preparing for infectious disease pandemics. Dr. Palese has recruited some of the top microbiologists in the world to study viruses and emerging pathogens. And the Division of Infectious Diseases is at the forefront of research, treatment, and prevention of infectious diseases with investigations focused on improving patient outcomes and rapidly translating research findings into patient care.

For inquiries related to commercial licensing of the test, please contact Cynthia Cleto from Mount Sinai Innovation Partners at: [emailprotected]

If you have recently recovered from COVID-19,see if you qualify for convalescent plasma transfusion.

To support COVID-19 research and response efforts, visit https://www.mountsinai.org/covid19research.

Continue reading here:
Mt. Sinai Hospital's Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From FDA - The Jewish Voice

Read More...

Drinking filtered brew coffee is the healthiest, says study – Free Press Journal

Monday, April 27th, 2020

London: We may all be drinking more coffee to help us survive the coronavirus (COVID-19) lockdown, and now researchers have revealed that filtered brew is the safest and healthiest one.

The study, published in the European Journal of Preventive Cardiology, examined links between coffee brewing methods and risks of heart attacks and death and found that coffee drinking was not a dangerous habit. In fact, drinking filtered coffee was safer than no coffee at all. The lowest mortality was among consumers of 1 to 4 cups of filtered coffee per day."Unfiltered coffee contains substances which increase blood cholesterol. Using a filter removes these and makes heart attacks and premature death less likely," said study author Professor Dag S Thelle from the University of Gothenburg in Sweden.

According to the researchers, experiments identified the culprit substances in coffee and found that they could be removed using a filter. A cup of unfiltered coffee contains about 30 times the concentration of the lipid-raising substances compared to filtered coffee.

Between 1985 and 2003, the study enrolled a representative sample of the Norwegian population: 508,747 healthy men and women aged 20 to 79. Participants completed a questionnaire on the amount and type of coffee consumed.

Data was also collected on variables that could influence both coffee consumption and heart diseases, so that these could be accounted for in the analysis. For example, smoking, education, physical activity, height, weight, blood pressure, and cholesterol.

Participants were followed for an average of 20 years. A total of 46,341 participants died. Of those, 12,621 deaths were due to cardiovascular disease. Of the cardiovascular deaths, 6,202 were caused by a heart attack.Compared to no coffee, the filtered brew was linked with a 15 per cent reduced risk of death from any cause during follow up.

For death from cardiovascular disease, the filtered brew was associated with a 12 per cent decreased risk of death in men and a 20 per cent lowered risk of death in women compared to no coffee. "The finding that those drinking the filtered beverage did a little better than those not drinking coffee at all could not be explained by any other variable such as age, gender, or lifestyle habits. So we think this observation is true," Thelle said.

The filtered brew was also less risky than the unfiltered beverage for death from any cause, death due to cardiovascular disease and deaths from heart attacks. "Our analysis shows that this was partly because of the cholesterol-increasing effect of unfiltered coffee," Thelle explained.

The researchers noted that unfiltered coffee did not raise the risk of death compared to abstaining from coffee - except in men aged 60 and above, where unfiltered brew was linked with elevated cardiovascular mortality.

Read more from the original source:
Drinking filtered brew coffee is the healthiest, says study - Free Press Journal

Read More...

Page 6«..5678..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick